Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.

Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D.

EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6.

2.

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.

Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1631. doi: 10.3390/ijms20071631.

3.

Immunotherapy in malignant melanoma: recent approaches and new perspectives.

Arasanz H, Lacalle A, Lecumberri MJ, de Lascoiti ÁF, Blanco-Luquin I, GatoCañas M, Pérez-Ricarte L, Zuazo M, Kochan G, Escors D.

Melanoma Manag. 2017 Mar;4(1):39-48. doi: 10.2217/mmt-2016-0019. Epub 2017 Mar 1. Review.

4.

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, Estival A, Vicente D, Rubió J, Martin-Broto J.

Clin Transl Oncol. 2016 Dec;18(12):1221-1228. doi: 10.1007/s12094-016-1579-9. Epub 2016 Nov 28.

5.

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D.

BMC Cancer. 2016 Feb 22;16:135. doi: 10.1186/s12885-016-2084-9.

6.

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, Tamés MJ, Muros B, Lecumberri MJ, Feliu J, Martínez P, Adansa JC, Martínez MJ, López R, Blasco A, Gascón P, Calvo V, Luna P, Montalar J, Del Barrio P, Tornamira MV.

Support Care Cancer. 2015 Sep;23(9):2841. doi: 10.1007/s00520-015-2842-2. No abstract available.

7.

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, Tamés MJ, Muros B, Lecumberri MJ, Feliu J, Martínez P, Adansa JC, Martínez MJ, López R, Blasco A, Gascón P, Calvo V, Luna P, Montalar J, Del Barrio P, Tornamira MV.

Support Care Cancer. 2015 Sep;23(9):2833-40. doi: 10.1007/s00520-015-2809-3. Epub 2015 Jun 17. Erratum in: Support Care Cancer. 2015 Sep;23(9):2841.

8.

Determinants of patient satisfaction with care in a Spanish oncology day hospital and its relationship with quality of life.

Arraras JI, Illarramendi JJ, Viudez A, Ibáñez B, Lecumberri MJ, de la Cruz S, Hernandez B, Zarandona U, Cambra K, Martinez M, Salgado E, Lainez N, Vera R.

Psychooncology. 2013 Nov;22(11):2454-61. doi: 10.1002/pon.3307. Epub 2013 Jun 4.

PMID:
23733231
9.

The cancer outpatient satisfaction with care questionnaire for chemotherapy, OUT-PATSAT35 CT: a validation study for Spanish patients.

Arraras JI, Illarramendi JJ, Viudez A, Lecumberri MJ, de la Cruz S, Hernandez B, Zarandona U, Bredart A, Martinez M, Salgado E, Lainez N, Vera R.

Support Care Cancer. 2012 Dec;20(12):3269-78. doi: 10.1007/s00520-012-1467-y. Epub 2012 May 2.

PMID:
22549507
10.

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.

Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Gil-Arnaiz I, Lambea J, Lecumberri MJ, Cruz JJ.

Br J Cancer. 2010 Jun 8;102(12):1687-91. doi: 10.1038/sj.bjc.6605697. Epub 2010 May 18.

11.

Skull metastasis from rectal gastrointestinal stromal tumours.

Gil-Arnaiz I, Martínez-Trufero J, Pazo-Cid RA, Felipo F, Lecumberri MJ, Calderero V.

Clin Transl Oncol. 2009 Sep;11(9):625-7.

PMID:
19776004

Supplemental Content

Loading ...
Support Center